342 related articles for article (PubMed ID: 22342301)
1. Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of radiation-induced lumbosacral plexopathy.
Yi SK; Mak W; Yang CC; Liu T; Cui J; Chen AM; Purdy JA; Monjazeb AM; Do L
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):376-82. PubMed ID: 22342301
[TBL] [Abstract][Full Text] [Related]
2. External validation of the lumbosacral plexus-contouring protocol developed by Yi et al. (IJROBP 2012; 84: 376-82) for pelvic malignancies.
Min M; Roos D; Keating E; Kerr L; Mukherjee R; Potter A; Shakeshaft J; Baxi S
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):117-24. PubMed ID: 24529065
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer.
Hall WH; Guiou M; Lee NY; Dublin A; Narayan S; Vijayakumar S; Purdy JA; Chen AM
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1362-7. PubMed ID: 18448267
[TBL] [Abstract][Full Text] [Related]
4. Lumbosacral plexus delineation, dose distribution, and its correlation with radiation-induced lumbosacral plexopathy in cervical cancer patients.
Tunio M; Al Asiri M; Bayoumi Y; Abdullah O Balbaid A; AlHameed M; Gabriela SL; Amir O Ali A
Onco Targets Ther; 2015; 8():21-7. PubMed ID: 25565862
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
[TBL] [Abstract][Full Text] [Related]
7. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
8. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
[TBL] [Abstract][Full Text] [Related]
9. Validating the RTOG-endorsed brachial plexus contouring atlas: an evaluation of reproducibility among patients treated by intensity-modulated radiotherapy for head-and-neck cancer.
Yi SK; Hall WH; Mathai M; Dublin AB; Gupta V; Purdy JA; Chen AM
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1060-4. PubMed ID: 21536393
[TBL] [Abstract][Full Text] [Related]
10. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer.
Ng M; Leong T; Chander S; Chu J; Kneebone A; Carroll S; Wiltshire K; Ngan S; Kachnic L
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1455-62. PubMed ID: 22401917
[TBL] [Abstract][Full Text] [Related]
11. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
Patel PR; Yoo S; Broadwater G; Marks LB; Miles EF; D'Amico TA; Harpole D; Kelsey CR
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):362-8. PubMed ID: 22516382
[TBL] [Abstract][Full Text] [Related]
12. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
[TBL] [Abstract][Full Text] [Related]
13. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
[TBL] [Abstract][Full Text] [Related]
16. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
18. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
19. Importance of protocol target definition on the ability to spare normal tissue: an IMRT and 3D-CRT planning comparison for intraorbital tumors.
Hein PA; Gladstone DJ; Bellerive MR; Hug EB
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1540-8. PubMed ID: 16029816
[TBL] [Abstract][Full Text] [Related]
20. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
